Showing Results for
- Academic Journals (38)
Search Results
- 38
Academic Journals
- 38
- Search Terms:
- 1From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedEpidemiological studies on the association between SULT1A1 codon 213 polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was conducted...
- 2From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedMany missense variants in BRCA1 are of unclear clinical significance. Functional and genetic approaches have been proposed for elucidating the clinical significance of such variants. The purpose of this study was to...
- 3From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedTargeting HER-2 over-expressing breast cancer cells with trastuzumab has resulted in significant improvements in both disease-free and overall survival rates. However, despite a favorable initial response, some cancer...
- 4From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedPrevious studies have demonstrated that the persistent exposure of human bronchial epithelial cells to nicotine (Nic) through nicotinic acetylcholine receptors increases cyclin D1 promoter activity and protein...
- 5From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedTo the Editor, Recently, we read with interest the article by Yu et al. [1]. They performed a meta-analysis to make an estimation of the association between two single-nucleotide polymorphisms (SNPs) in the...
- 6From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedMistakes in DNA repair can result in sustained damage and genetic instability. We comprehensively evaluated common variants in DNA repair pathway genes for their association with postmenopausal breast cancer risk with...
- 7From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedTo determine whether zoledronic acid (ZA) can prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. In this randomized, open-label, phase III multicenter trial, premenopausal women...
- 8From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedThe purpose of this study is to investigate 1-year adherence rates to aromatase inhibitors (AI) and to determine risk factors for non-adherence among commercially insured post-menopausal breast cancer patients. A...
- 9From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedConflicting data have been published as to the possible association between polymorphism in codon 72 of the TP53 tumor suppressor gene and the risk of developing breast cancer. In order to address this question, we...
- 10From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedGlutathione S-transferase P1 (GSTP1) is involved in a wide range of detoxifying reactions. Any alteration in the structure, function, or expression of GSTP1 gene may alter the ability of a cell to inactivate carcinogens...
- 11From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedPathological complete response (pCR) to neoadjuvant treatment correlates with outcome in breast cancer. We determined whether characteristics of neoadjuvant therapy are associated with pCR. We used multi-level models,...
- 12From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedBreast cancer incidence has markedly increased in Western countries for reasons that are not entirely understood. We characterized periodic and age-specific incidence trends of breast cancer in immigrants who migrated...
- 13From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedSeveral studies have investigated the associations between AURKA T91A polymorphism and the susceptibility to breast cancer, but the results have been inconclusive. To derive a more precise estimation of the...
- 14From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedResults from multinational clinical trials are globally adopted into the routine clinical practice in most countries. Changes in the natural history and incidence of certain diseases as well as in drugs toxicities...
- 15From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedTrastuzumab is a FDA-approved drug that has shown clinical efficacy against HER2+ breast cancers and is commonly used in combination with other chemotherapeutics. However, many patients are innately resistant to...
- 16From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedLapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients...
- 17From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedEvery-2-week (dose-dense) adjuvant doxorubicin (A) plus cyclophosphamide (C) followed by paclitaxel is a safe and effective adjuvant chemotherapy regimen. Every-3-week nab-paclitaxel is safe and more effective at 50%...
- 18From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedNicastrin is an essential component of the gamma secretase (GS) enzyme complex, required for its synthesis and recognition of substrates for proteolytic cleavage. The purpose of this study was to investigate whether...
- 19From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedSeveral studies have investigated the associations between RAD51 G135C polymorphism and the susceptibility to breast cancer, but results have been inconclusive. In order to derive a more precise estimation of the...
- 20From: Breast Cancer Research and Treatment. (Vol. 125, Issue 1) Peer-ReviewedResponse to fulvestrant and survival in postmenopausal hormone-sensitive advanced breast cancer was investigated within a non-randomized, In-Practice Evaluation Program, with the aim of optimizing treatment decisions....